Clinical Trial Details
| Trial ID: | L0510 |
| Source ID: | NCT05305495 |
| Associated Drug: | Empagliflozin 25 Mg |
| Title: | Empagliflozin in Acute Heart Failure |
| Acronym: | DRIP-AHF-1 |
| Status: | RECRUITING |
| Study Results: | NO |
| Results: | |
| Conditions: | Acute Heart Failure|Chronic Kidney Diseases |
| Interventions: | DRUG: Empagliflozin 25 MG |
| Outcome Measures: | Primary: Diuretic effect of empagliflozin in association with furosemide, Three-hour urine output post empagliflozin-furosemide administration, compared with furosemide alone, Day 1 | Secondary: Fractional excretion of sodium in the urine, FeNa (%), Day 1|Total urine sodium output, Urine sodium per 24h, Day 1-5|Changes in volume status, Net fluid balance, Day 1-5|Incidence of AKI, Using the conventional KDIGO criteria, Day 1-5|Electrolyte abnormalities - Sodium, Concentration of sodium, Day 1-5|Electrolyte abnormalities - Potassium, Concentration of potassium, Day 1-5|Electrolyte abnormalities - Magnesium, Concentration of magnesium, Day 1-5 |
| Sponsor/Collaborators: | Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 25 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2022-12-22 |
| Completion Date: | 2027-02 |
| Results First Posted: | |
| Last Update Posted: | 2025-01-08 |
| Locations: | Research Institute of the McGill University Health Center, Montreal, Quebec, Canada |
| URL: | https://clinicaltrials.gov/show/NCT05305495 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|